Pregabalin Capsule
Product Images NDC 68788-7524

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pregabalin Caps 150mg 30s Count

Pregabalin Caps 150mg 30s Count
This is a label for Pregabalin Capsules 150mg manufactured by ScieGen Pharmaceuticals, Inc. The caution mentions that federal law prohibits the transfer of the medication to a non-patient. The text also includes information on the drug's dosage, ingredients, lot number, expiration date, and generic name, Lyrica.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
The text shows a chart displaying percent of patients improved with the use of Pregabalin at 300mg and 450mg daily doses compared to placebo. The chart also indicates the percent improvement in pain from baseline.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
The text appears to be a chart or graph showing the estimated percentage of subjects without "LTR" for two treatments, Progabain and Placebo, over a period of 120 days. The percentages range from 0% to 100%. There are no further details available.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a formula for calculating CLCT (Creatinine Clearance). It involves multiplying a value obtained by taking 140 minus the patient's age in years by their weight in kilograms. The resulting value is then adjusted by multiplying it by 0.85 for female patients. The second part of the formula involves multiplying 72 by the level of serum creatinine in mg/dL. It is unclear what the purpose of CLCT is or how this formula is used without additional context.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.